Skip to main content
. Author manuscript; available in PMC: 2017 Sep 14.
Published in final edited form as: Nano Lett. 2016 Aug 10;16(9):5326–5332. doi: 10.1021/acs.nanolett.6b00902

Figure 4.

Figure 4

Therapy-resistant GSC exhibition of enhanced motility capabilities. (a) Single-cell motility assays showing that although both TMZ and anti-miR363 therapy had a significant negative effect on cell viability, only the anti-miR363 caused a significant and concomitant decrease in cell motility. (b) Continuous monitoring of single-cell motility following anti-miR363 delivery revealed that only the cells that were prone to undergoing apoptosis within the first 48 h showed a significant decrease in single-clone motility. Cells that had not undergone apoptosis past 48 h still showed marked motility, comparable to untreated and control cells. (c) In situ hybridization experiments coupled with drug-resistance studies by 3D NEP allowed us to identify the surviving and highly migratory cell population as being high in CD44 expression. Asterisks indicate p < 0.05 (Dunn’s method).